Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Ginsenoside-rg(1)
2. Panaxoside Rg1
3. Sanchinoside C(1)
4. Sanchinoside C1
1. 22427-39-0
2. Sanchinoside C1
3. Panaxoside A
4. Ginsenoside A2
5. Panaxoside Rg1
6. Sanchinoside Rg1
7. (3beta,6alpha,12beta)-3,12-dihydroxydammar-24-ene-6,20-diyl Bis-beta-d-glucopyranoside
8. (20s)-ginsenoside Rg1
9. Ginsenoside-rg1
10. Chebi:67987
11. Pj788634qy
12. Ginsenoside G1
13. Mfcd00210293
14. Chembl501637
15. Unii-pj788634qy
16. Ginsenosiderg1
17. Einecs 244-989-9
18. Bidd:er0075
19. Dammarane, -d-glucopyranoside
20. Schembl19875635
21. Dtxsid70945111
22. Ginsenoside Rg1 [usp-rs]
23. Ginsenoside Rg1 [who-dd]
24. Hms3885m12
25. Ex-a6784
26. Hy-n0045
27. Rg1
28. 6-(hexopyranosyloxy)-3,12-dihydroxydammar-24-en-20-yl Hexopyranoside
29. Ginsenoside Rg1, Analytical Standard
30. S3923
31. (6)-beta-d-glucopyranosyl-(20)-beta-d-glucopyranosyl-20s-protopanaxatriol
32. Akos037514672
33. Zinc238809655
34. Ccg-270492
35. Cs-3832
36. Db06750
37. Bs-16671
38. G0533
39. N1613
40. C08946
41. 427g390
42. A816192
43. Q-100285
44. Q2276594
45. 7-hydroxy-2-oxo-2h-chromene-3-carboxylicacidamide
46. Ginsenoside Rg1, Primary Pharmaceutical Reference Standard
47. Ginsenoside Rg1, United States Pharmacopeia (usp) Reference Standard
48. (3b,6a,12b)-3,12-dihydroxydammar-24-ene-6,20- Diylbis(beta-d-glucopyranoside)
49. (3beta,6alpha,12beta)-3,12-dihydroxydammar-24-ene-6,20-diylbis(beta-d-glucopyranoside)
50. (6)-.beta.-d-glucopyranosyl-(20)-.beta.-d-glucopyranosyl-20s- Protopanaxatriol
51. Beta-d-glucopyranoside, (3beta,6alpha,12beta)-3,12-dihydroxy Dammar-24-ene-6,20-diylbis-
52. Beta-d-glucopyranoside, (3beta,6alpha,12beta)-3,12-dihydroxydammar-24-ene-6,20-diyl Bis-
53. (2r,3r,4s,5s,6r)-2-(((3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-((s)-6-methyl-2-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)hept-5-en-2-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-6-yl)oxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
54. (3.beta.,6.alpha.,12.beta.)-3,12-dihydroxydammar-24-ene-6,20- Diylbis(.beta.-d-glucopyranoside)
55. (3beta,alpha,12beta)-20-(beta-d-glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl Beta-d-glucopyranoside
56. .beta.-d-glucopyranoside, (3.beta.,6.alpha.,12.beta.)-3,12- Dihydroxy Dammar-24-ene-6,20-diylbis-
57. .beta.-d-glucopyranoside, (3.beta.,6.alpha.,12.beta.)-3,12-dihydroxydammar-24-ene-6,20-diyl Bis-
58. Ginsenoside Rg1 (constituent Of American Ginseng, Asian Ginseng, And Tienchi Ginseng) [dsc]
| Molecular Weight | 801.0 g/mol |
|---|---|
| Molecular Formula | C42H72O14 |
| XLogP3 | 2.7 |
| Hydrogen Bond Donor Count | 10 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 10 |
| Exact Mass | 800.49220697 g/mol |
| Monoisotopic Mass | 800.49220697 g/mol |
| Topological Polar Surface Area | 239 Ų |
| Heavy Atom Count | 56 |
| Formal Charge | 0 |
| Complexity | 1410 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 21 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Central Nervous System Agents
A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into "specific" agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and "nonspecific" agents, those producing effects on different target cells and acting by diverse molecular mechanisms. Those with nonspecific mechanisms are generally further classed according to whether they produce behavioral depression or stimulation. Those with specific mechanisms are classed by locus of action or specific therapeutic use. (From Gilman AG, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p252) (See all compounds classified as Central Nervous System Agents.)
M1 (20- O -- D -glucopyranosyl-20( S )- protopanaxadiol ) is a ppd-type monoglucoside ginsenoside metabolized by intestinal bacteria in humans
REF. STANDARDS & IMPURITIES
ANALYTICAL
Analytical Methods
ABOUT THIS PAGE
58
PharmaCompass offers a list of Ginsenoside Rg1 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ginsenoside Rg1 manufacturer or Ginsenoside Rg1 supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ginsenoside Rg1 manufacturer or Ginsenoside Rg1 supplier.
PharmaCompass also assists you with knowing the Ginsenoside Rg1 API Price utilized in the formulation of products. Ginsenoside Rg1 API Price is not always fixed or binding as the Ginsenoside Rg1 Price is obtained through a variety of data sources. The Ginsenoside Rg1 Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ginsenoside Rg1 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ginsenoside Rg1, including repackagers and relabelers. The FDA regulates Ginsenoside Rg1 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ginsenoside Rg1 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Ginsenoside Rg1 supplier is an individual or a company that provides Ginsenoside Rg1 active pharmaceutical ingredient (API) or Ginsenoside Rg1 finished formulations upon request. The Ginsenoside Rg1 suppliers may include Ginsenoside Rg1 API manufacturers, exporters, distributors and traders.
Ginsenoside Rg1 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ginsenoside Rg1 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ginsenoside Rg1 GMP manufacturer or Ginsenoside Rg1 GMP API supplier for your needs.
A Ginsenoside Rg1 CoA (Certificate of Analysis) is a formal document that attests to Ginsenoside Rg1's compliance with Ginsenoside Rg1 specifications and serves as a tool for batch-level quality control.
Ginsenoside Rg1 CoA mostly includes findings from lab analyses of a specific batch. For each Ginsenoside Rg1 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ginsenoside Rg1 may be tested according to a variety of international standards, such as European Pharmacopoeia (Ginsenoside Rg1 EP), Ginsenoside Rg1 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ginsenoside Rg1 USP).
